Table 3.
Medical management
| Elderly patients (EPs), n = 30 | Young patients (YPs), n = 60 | p | |
|---|---|---|---|
| Corticosteroids, n (%) | 14 (46.7%) | 37 (61.7%) | 0.17 |
| Immunosuppressants | |||
| monotherapy, n (%) | 10 (33.3%) | 35 (58.3%) | 0.02 |
| Azathioprine, n (%) | 10/10 (100%) | 33/35 (94.3%) | |
| Methotrexate, n (%) | 3/10 (33.3%) | 5/35 (14.3%) | |
| Other, n (%) | 1/10 (10%) | 2/35 (5.7%) | |
| Anti-TNF alpha, n (%) | 26 (86.7%) | 58 (96.7%) | 0.07 |
| Optimization | 10/26 (38.5%) | 44/58 (75.9%) | 0.0002 |
| use in combination therapy | 14/26 (53.9%) | 51/58 (87.9%) | 0.0001 |
| agent: | |||
| - Infliximab, n (%) | 22/26 (84.6%) | 55/58 (94.8%) | |
| - Adalimumab, n (%) | 11/26 (42.3%) | 39/58 (67.2%) | |
| - Golimumab, n (%) | 0/26 (0%) | 5/58 (8.6%) | |
| Other biotherapies, n (%) | 12 (40%) | 24 (40%) | |
| - Vedolizumab, n (%) | 1/12 (8.3%) | 9/24 (37.5%) | |
|
- Ustekinumab, n (%) -Other§, n (%) |
11/12 (91.7%) 1/12 (8.3%) |
20/24 (83.3%) 6/24 (25%) |
|
EPs age at first surgery ≥ 60, YPs age at first surgery < 60
§Certolizumab, Filgotinib